{
  "source": "PA-Notification-Winrevair.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1448-2\nProgram Prior Authorization/Notification\nMedication Winrevair ™ (sotatercept-csrk)\nP&T Approval Date 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nWinrevair (sotatercept-csrk) is an activin signaling inhibitor indicated for the treatment of adults\nwith pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity,\nimprove WHO functional class (FC) and reduce the risk of clinical worsening events.1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Winrevair will be approved based on the following criterion:\na. Diagnosis of pulmonary arterial hypertension\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Winrevair will be approved based on the following criterion:\na. Documentation of positive clinical response to Winrevair therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limitations may be in place.\n4. References:\n1. Winrevair [package insert]. Rahway, NJ: Merck & Co., Inc; March 2024\n© 2025 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification – Winrevair ™ (sotatercept-csrk)\nChange Control\n6/2024 New program\n6/2025 Annual review. No changes to coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}